Getting started with Optune

Welcome to the family

A couple of years ago, we welcomed a new family member into our home…My little Optune came in a big blue case delivered by nCompass, Novocure’s support program. That first day, a Device Support Specialist (DSS) came out to my house and showed me how to use Optune. I was excited, but a few pesky questions kept buzzing around in my brain: Could I take care of this new addition? Would things work out? And, most importantly, does he bite? (I’m kidding about that last one, of course.)

That first night

After the DSS left, we prepared for our first night with Optune. I plugged the unit in and it sat waiting for me quietly, tail wagging, next to the bed. I was worried it would keep me up all night and that there would be a lot of noise. But, to my surprise, it went well—aside from causing me to have a very itchy scalp!

Settling in

Not long into using Optune, I decided to try changing the arrays myself. I figured that if other people could do it, so could I!

“If I’m being totally honest…my work wasn’t the prettiest. Not even close. But I got the job done. And, most importantly, everything was in the correct spot. Changing the arrays myself allowed me to have a little more independence. Now that I’ve been at it awhile, it’s like tying a shoe…or, even, walking a dog.”

Of course, it also helps that my husband is great at placing the arrays if I need to avoid a certain area. He’s also pretty good at making sure Optune is always ready to go. I count on him to check the battery level before we head out the door.

Sherry1.jpgPart of the family

Although Optune is no longer new to me, my DSS and I keep in touch regularly to make sure I’m still comfortable using the device. We have a good rapport and I enjoy talking with her. Still, I make sure to do my part to keep things flowing smoothly.

Everyone has gotten used to Optune being around. I wouldn’t exactly call the transition seamless, but I now consider it a loyal member of my household.
 

Topics: Learning About Optune, Daily Life with Optune, The Optune System
By By: Sherry, Optune® patient - 58, Boalsburg, PA

Connect With an Optune Buddy

Find out how a Buddy could help answer your questions.

Schedule a chat  ▶

What is Optune® approved to treat?

Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:

Recurrent GBM

If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:

What is Optune Lua approved to treat?

Optune Lua is a wearable, portable, FDA-approved device indicated for the treatment of adult patients, with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used together with standard chemotherapy (pemetrexed and platinum-based chemotherapy).

Who should not use Optune for GBM or Optune Lua for MPM?

Optune for GBM and Optune Lua for MPM are not for everyone. Talk to your doctor if you have:

Do not use Optune for GBM or Optune Lua for MPM if you are pregnant or are planning to become pregnant. It is not known if Optune/Optune Lua is safe or effective during pregnancy.

What should I know before using Optune for GBM or Optune Lua for MPM?

Optune and Optune Lua should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune and Optune Lua.

What are the possible side effects of Optune for GBM and Optune Lua for MPM?

The most common side effects of Optune when used together with chemotherapy for GBM (temozolomide or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, seizure, and depression.

The most common side effects when using Optune alone for GBM were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

The most common side effects of Optune Lua when used together with chemotherapy for MPM (pemetrexed and platinum-based chemotherapy) were low red blood cell count, constipation, nausea, tiredness, chest pain, fatigue, skin irritation from device use, itchy skin, and cough.

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin irritation, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

Talk to your doctor if you have any of these side effects or questions.

Caution: Federal law restricts Optune Lua to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Please click here to see the Optune Lua IFU for complete information regarding the device's indications, contraindications, warnings, and precautions.

On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals. Patient images reflect the health status of the patients at the time each photo was taken.

What is Optune approved to treat?

Optune is indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.